| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 504 |
| Referral date | 01 November 2011 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 22 June 2012 |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Laura Gibson |
| Executive Lead: | TBC |
| Project manager: | Rebecca Pye |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in July 2012, the appraisal of Romidepsin for the treatment of relapsed or refractory peripheral T-cell lymphoma [ID504] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 23 November 2012 |
Following an update on the regulatory status of this technology which has received a negative CHMP opinion, this appraisal remains suspended whilst we consider the next steps. |
| 10 July 2012 |
The manufacturer of romidepsin has informed NICE that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal. |
| 22 February 2012 |
Following on from advice received from the manufacturer, this appraisal has now been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late April 2012 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2012. |
For further information on our processes and methods, please see our CHTE processes and methods manual